(Journal Article): A Case of Acquired Generalized Lipodystrophy with Cerebellar Degeneration and Type 2 Diabetes Mellitus
 
Chao PJ, Tsai JCR, Chang DM, Shin SJ, Lee YJ (Department of Internal Medicine, Pingtung Christian Hospital, Pingtung, 90000 Taiwan, t3275(at)ms25.hinet.net )
 
IN: Rev Diabetic Stud 2004; 1(4):193-197
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Acquired generalized lipodystrophy (AGL) is a rare disorder of adipose tissue characterized by loss of fat from large regions of the body, occurring after birth. Its etiology remains unknown. Most AGL patients have had fasting and/or postprandial hyperinsulinemia, diabetes mellitus, hypertriglyceridemia, and fatty liver. We describe the case of a 30-year-old woman with a progressively unsteady gait and a generalized loss of body fat beginning at the age of 7. Cerebellar degeneration was revealed by imaging study, and the patient was eventually bedridden at the age of 15, due to progressive ataxia. She developed diabetes at the age of 25 without the presence of any evidence of ketoacidosis. The glutamic acid decarboxylase antibody was negative, C-peptide level 3.6 ng/ml, HbA1c 13%, triglyceride 412 mg/dl, total cholesterol 196 mg/dl, high-density lipoprotein-cholesterol 28 mg/dl, adiponectin 0.76 mcg/ml, and resistin was 22.8 ng/ml at the initial state of diabetes. AGL accompanied by type 2 diabetes and cerebellar degeneration was diagnosed on the basis of the clinical features and metabolic derangements.

TYPE OF PUBLICATION: Case Report

REFERENCES:

1. Smith DO, LeRoith D. Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. Clin Cornerstone 2004. 6:7-6.
2. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002. 967:363-378.
3. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004. 89:463-478.
4. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002. 23:201-229.
5. Garg A. Lipodystrophies. Am J Med 2000, 108:143-152.
6. Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endrocrinol Metab Clin N Am 2004. 33:305-331.
7. Garg A. Regional adiposity and insulin resistance. J Clin Endocrinol Metab 2004. 89:4206-4210.
8. Ziegler LH. Lipodystrophies: report of seven cases. Brain 1928. 51:145-167.
9. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 2003. 82:129-146.
10. Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipemia, and other metabolic disturbances. Lancet 1946. 1:724-731.
11. Pardini VC, Victoria IM, Rocha SM, Andrade DG, Rocha AM, Pieroni FB, Milagres G, Purisch S, Velho G. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab 1998. 83:503-508.
12. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004. 350:1220-1234.
13. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002. 87:2395-2398.
14. Sarai T, Kawanishi K, Saito Y, Aoi K, Nishina Y, Ofuji T. Lipoatrophic diabetes. Report of a case. Act Med Okayama 1978. 32:309-318.
15. Vantyghem MC, Vigouroux C, Magre J, Desbois-Mouthon C, Pattou F, Fontaine P, Lefebvre J, Capeau J. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. Diabetes Care 1999. 22:1374-1376.
16. Panz VR, Wing JR, Raal FJ, Kedda MA, Joffe BI. Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? Clin Endocrinol 1997. 46:365-368.
17. Hubler A, Abendroth K, Keiner T, Stocker W, Kauf E, Hein G, Stein G. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes 1998. 106:79-84.
18. Iglesias P, Fidalgo PA, Codoceo R, Diez JJ. Lipoatrophic diabetes in an elderly woman: Clinical course and serum adipocytokine concentrations. Endrocrine Journal 2004. 51:279-286.
19. Berger JR, Oral EA, Taylor SI. Familial lipodystrophy associated with neurodegeneration and congenital cataracts. Neurology 2002. 58:43-47.
20. Aminoff MJ, Greeberg DA, Simon RP. Clinical Neurology. Prentice-Hall International, Inc. 1996, Chapter 4, pp110-120.
21. Cooke WT, Thomas-Smith W. Neurological disorders associated with adult celiac disease. Brain 1966. 89:683-722.
22. Wenning GK, Colosimo C, Feser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004. 3:93-103.
23. Shill HA, Alaedini A, Latov N, Hallett M. Anti-ganglioside antibodies in idiopathic and hereditary cerebellar degeneration. Neurology 2003. 60:1672-1673.
24. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002. 346:570-578.
25. Van Gaal LF, Mertens IL, Abrams PJ. Health risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormone. Growth Horm IGF Res 2003. 13 Suppl A:S4-S9.
26. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002. 109:1345-1350.
27. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003. 52:910-917.
28. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000. 133:263-274.
29. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002. 51:7-18.
30. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab 2000. 11:410-416.
31. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001. 1930-1935.